Dupilumab normalizes the eosinophilic esophagitis disease transcriptome

Dupilumab, which blocks interleukin (IL)-4 and IL-13 signaling, is approved in eosinophilic esophagitis (EoE) and several other type 2 inflammatory diseases. We show that dupilumab normalizes the dysregulated esophageal transcriptome in pediatric, adolescent, and adult patients with EoE, including both eosinophil-related and eosinophil-independent biologic pathways. Changes in the esophageal transcriptome were analyzed from pre- and post-treatment esophageal biopsies provided by patients with EoE who participated in one of three placebo-controlled clinical trials of dupilumab including pediatric, adolescent and adult patients. This study includes RNA-seq data for 2887 samples. Term definitions: VISIT: SCR: screening EOT: end of treatment ET: early termination U1: unscheduled WK24: week 24 WK52: week 52 TREATMENT: pbo: placebo qw: weekly q2w: every 2 weeks lo: low-exposure hi: high-exposure *************************************************************** Raw files for human/patient samples were not submitted to GEO due to concerns about submitting personally identifiable sequence data for open access. ***************************************************************

度普利尤单抗（dupilumab）可阻断白细胞介素（interleukin, IL）-4与IL-13信号通路，已获批用于嗜酸性粒细胞性食管炎（eosinophilic esophagitis, EoE）及其他多种2型炎症性疾病。本研究证实，度普利尤单抗可使儿童、青少年及成人嗜酸性粒细胞性食管炎患者的食管转录组失调状态恢复正常，涵盖嗜酸性粒细胞相关及非嗜酸性粒细胞相关的生物学通路。
研究对参与度普利尤单抗三项安慰剂对照临床试验之一的EoE患者的治疗前后食管活检组织的转录组变化进行了分析，受试人群涵盖儿童、青少年与成人患者。本研究包含2887个样本的RNA测序（RNA-seq）数据。
术语定义：
访视（VISIT）：SCR（筛查）；EOT（治疗结束）；ET（提前终止治疗）；U1（非计划访视）；WK24（第24周）；WK52（第52周）
治疗分组（TREATMENT）：pbo（安慰剂组）；qw（每周给药）；q2w（每2周给药）；lo（低暴露组）；hi（高暴露组）
****************************************************************
由于担忧将可识别个人身份的测序数据提交至开放获取平台，本研究未将人类/患者样本的原始文件上传至基因表达数据库（Gene Expression Omnibus, GEO）。
****************************************************************